Additional file 1 of Perturbed gut microbiome and fecal and serum metabolomes are associated with chronic kidney disease severity

Additional file 1: Additional Tables 1–10. Additional tables are separated in sheets in a single excel file. The first line in each sheet contains the title of each additional table. Supplementary Table 1. Post-hoc multiple analysis for study population characteristics. Supplementary Table 2. Comparisons of micaobial alpha diversity, beta diversity and taxa in each of the CKD groups with controls. Supplementary Table 3. Spearman correlation analysis between clinical data and CKD severity-specific species. Supplementary Table 4. Significant KO genes of those four metabolism pathways between each of the CKD groups and healthy controls. Supplementary Table 5. All differential fecal metabolites among each of the CKD groups and controls (VIP>1, FDR<0.05). Supplementary Table 6. All differential serum metabolites among each of the CKD groups and controls (VIP>1, FDR<0.05). Supplementary Table 7. Comparison of fecal metabolites related to Arginine and proline metabolism, Arachidonic acid metabolism, Ubiquinone and other terpenoid-quinone biosynthesis and Glutathione metabolism between each of the CKD groups and healthy control group.Statistical analysis was performed by Wilcoxon rank-sum test. Benjamini-Hochberg procedure was employed for the multiple test adjustments. Supplementary Table 8. Comparison of serum metabolites related to Arginine and proline metabolism, Arachidonic acid metabolism, Ubiquinone and other terpenoid-quinone biosynthesis and Glutathione metabolism between each of the CKD groups and healthy control group.Statistical analysis was performed by Wilcoxon rank-sum test. Benjamini-Hochberg procedure was employed for the multiple test adjustments. Supplementary Table 9. Spearman correlation analysis between clinical data and CKD severity-specific metabolites. Supplementary Table10. Performance of random-forest models discriminating CKD patients at different groups from controls based on 100-fold Cross-Validation.